4.5 Article

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease

期刊

HEPATOLOGY RESEARCH
卷 52, 期 6, 页码 508-521

出版社

WILEY
DOI: 10.1111/hepr.13757

关键词

biomarker; early stage of fibrosis; NAFLD; NASH; sCD14

资金

  1. Japan Agency for Medical Research and Development (AMED) [JP20fk0210053, JP20fk0310103, JP20fk0210072, JP20fk0210056, JP20fk0310101, JP20fk0210067]
  2. JSPS KAKENHI [JP20K08371, JP19K18956]

向作者/读者索取更多资源

This study evaluated the value of soluble CD14 (sCD14) as a diagnostic marker for distinguishing NASH from NAFLD, and found that sCD14 has high accuracy in differentiating between the two conditions. The results indicate that sCD14 could be a useful tool for identifying and screening high-risk groups for NASH development, as well as supporting early therapeutic interventions.
Background and Aims Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14) as a diagnostic marker for discriminating NASH from nonalcoholic fatty liver disease (NAFLD) using an animal model and clinical specimens. Methods Serum sCD14 levels were measured in samples derived from mice with diet-induced NASH and patients using an enzyme-linked immunosorbent assay. Our cohort enrolled 126 patients with liver needle biopsy-proven NAFLD. Results The intestinal defense mechanism in NASH model mice was altered as a consequence of the unique gut environment. Elevated serum levels of sCD14 were observed in mice with diet-induced NASH, and the condition of the liver was exacerbated as a result of exposure to gut-derived endotoxin. We confirmed that the serum sCD14 levels in NAFL patients significantly differed from those in NASH patients. The area under the curve for distinguishing between NAFL and NASH was 0.891. Moreover, we found that serum sCD14 levels were weakly correlated with the inflammation grade based on the NAFLD activity score (NAS), the grade of fibrosis according to the Brunt fibrosis classification, and a positive correlation with the grade of ballooning based on NAS in patients with NAFLD. Conclusion sCD14 could be a useful pathophysiological marker and diagnostic adjunct distinguishing NASH from NAFLD. The use of sCD14 may allow the screening and identification of high-risk groups for NASH development and support early therapeutic interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据